Stem cell research in the laboratory of the Integrated Service Unit for Stem Cell Medical Technology RSCM-FKUI, Jakarta, Thursday (8/9/2016). This place provides and organizes stem cell service, processing, education, development, and research activities in hospitals.
JAKARTA, KOMPAS — The use of mesenchymal stem cells from the umbilical cord is increasingly promising as an additional therapy for Covid-19 patients in critical condition with comorbidities. International publications related to this therapy have also been published by researchers. It is hoped that the use permit from the Food and Drug Supervisory Agency can be immediately granted so that its utilization can be wider.
Professor of Orthopedics and Traumatology from the Faculty of Medicine, University of Indonesia Ismail Hadisoebroto Dilogo said that mesenchymal stem cell therapy from the umbilical cord given via intravenous infusion was able to increase the life expectancy of critically ill Covid-19 patients. These are the results of the research “Application of Mesenchymal Stem Cells from the Cord as Adjuvant Therapy in Critically Covid-19 Pneumonia Patients” conducted by Ismail with other researchers and has been published in Stem Cell Translational Medicine Journal June 8, 2021.
–
